Medicare Enrolled
Dr. Rene Rubin, MD
Hematology & Oncology · Philadelphia, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rubin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rubin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rubin
Dr. Rene Rubin is a hematology & oncology specialist in Philadelphia, PA, with 21 years of NPI registration. Based on federal Medicare data, Dr. Rubin performed 42,365 Medicare services across 1,069 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rubin received a total of $33,324 from 109 pharmaceutical and/or device companies across 912 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rubin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 21 years in practice
▲ Top 13% volume in PA
$33,324 industry payments
Medicare Practice Summary
Medicare Utilization ↗42,365
Medicare services
Top 13% in PA for hematology & oncology
1,069
Unique beneficiaries
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,017 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 18,000 | $38 | $60 |
| Denosumab injection (Prolia/Xgeva) | 7,380 | $18 | $37 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
5,815 | $0 | $1 |
| Anti-nausea injection (ondansetron/Zofran) | 4,294 | $0 | $1 |
| Iron infusion (Monoferric) | 1,800 | $16 | $35 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,053 | $98 | $200 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
903 | $8 | $12 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
902 | $8 | $20 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
753 | $24 | $85 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
396 | $107 | $335 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
234 | $12 | $45 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
180 | $0 | $5 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
125 | $54 | $140 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
103 | $54 | $150 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
102 | $1 | $3 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
85 | $7 | $25 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
83 | $1 | $5 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
46 | $65 | $150 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
40 | $71 | $150 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
36 | $119 | $350 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
35 | $98 | $175 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
7.9% high complexity
85.0% medium
7.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$33,324
Total received (2018-2024)
Avg $4,761/year across 7 years
Top 11% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
109
Companies
912
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,849 (59.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,997 (27.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,292 (6.9%)
Other
Charitable contributions, space rental, and other categories
$2,185 (6.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,277
2023
$5,055
2022
$4,970
2021
$4,249
2020
$3,760
2019
$6,597
2018
$4,415
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$310
Novartis Pharmaceuticals Corporation
$228
GENZYME CORPORATION
$215
PFIZER INC.
$191
Incyte Corporation
$176
Genmab U.S., Inc.
$169
ABBVIE INC.
$166
AstraZeneca Pharmaceuticals LP
$160
Ferring Pharmaceuticals Inc.
$146
Janssen Scientific Affairs, LLC
$144
Daiichi Sankyo Inc.
$142
Fennec Pharmaceuticals, Inc.
$133
SOBI, INC
$131
EMD Serono, Inc.
$128
Merck Sharp & Dohme LLC
$122
Astellas Pharma US Inc
$113
GlaxoSmithKline, LLC.
$110
Eisai Inc.
$98
Acrotech Biopharma Inc.
$82
Pharmacosmos Therapeutics Inc.
$82
ARRAY BIOPHARMA INC
$74
Cook Medical LLC
$72
Bayer Healthcare Pharmaceuticals Inc.
$72
Tempus AI, Inc
$71
Celgene Corporation
$66
Gilead Sciences, Inc.
$65
E.R. Squibb & Sons, L.L.C.
$62
Blueprint Medicines Corporation
$58
Stemline Therapeutics Inc.
$49
PUMA BIOTECHNOLOGY, INC.
$49
Amneal Pharmaceuticals LLC
$48
Regeneron Healthcare Solutions, Inc.
$47
RECORDATI_RARE_DISEASES_INC.
$47
Apellis Pharmaceuticals, Inc.
$46
Exelixis Inc.
$42
Genentech USA, Inc.
$41
Takeda Pharmaceuticals U.S.A., Inc.
$40
Ipsen Biopharmaceuticals, Inc
$29
Alexion Pharmaceuticals, Inc.
$28
JAZZ PHARMACEUTICALS INC.
$27
Kyowa Kirin, Inc.
$27
BeiGene USA, Inc.
$25
SERVIER PHARMACEUTICALS LLC
$25
Mirati Therapeutics, Inc.
$22
PharmaEssentia USA Corporation
$21
SpringWorks Therapeutics, Inc.
$21
Secura Bio, Inc.
$20
Adaptive Biotechnologies Corporation
$19
Geron Corporation
$19
Top 3 companies account for 17.6% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$3,405
TESARO, Inc.
$3,085
Novartis Pharmaceuticals Corporation
$2,958
Celgene Corporation
$2,094
Bayer HealthCare Pharmaceuticals Inc.
$1,814
GENZYME CORPORATION
$1,235
E.R. Squibb & Sons, L.L.C.
$1,074
PFIZER INC.
$1,032
AstraZeneca Pharmaceuticals LP
$1,004
Astellas Pharma US Inc
$962
Seagen Inc.
$852
Amgen Inc.
$828
Incyte Corporation
$626
Daiichi Sankyo Inc.
$572
Pharmacyclics LLC, An AbbVie Company
$530
NOVARTIS PHARMACEUTICALS CORPORATION
$449
Eisai Inc.
$436
ABBVIE INC.
$397
Merck Sharp & Dohme Corporation
$387
Pharmacosmos Therapeutics Inc.
$375
EMD Serono, Inc.
$342
GlaxoSmithKline, LLC.
$339
Genentech USA, Inc.
$330
Gilead Sciences, Inc.
$329
Genmab U.S., Inc.
$324
Kyowa Kirin, Inc.
$310
Janssen Scientific Affairs, LLC
$289
Merck Sharp & Dohme LLC
$282
SANOFI-AVENTIS U.S. LLC
$275
Global Blood Therapeutics, Inc.
$267
Blueprint Medicines Corporation
$264
ARRAY BIOPHARMA INC
$263
Kite Pharma, Inc.
$258
Stemline Therapeutics Inc.
$254
Exelixis Inc.
$248
Foundation Medicine, Inc.
$238
Lilly USA, LLC
$227
Regeneron Healthcare Solutions, Inc.
$196
Bayer Healthcare Pharmaceuticals Inc.
$172
Acrotech Biopharma Inc.
$158
SOBI, INC
$154
Ferring Pharmaceuticals Inc.
$146
Fennec Pharmaceuticals, Inc.
$133
AbbVie Inc.
$128
Epizyme, Inc.,
$122
Coherus Biosciences Inc.
$115
Boehringer Ingelheim Pharmaceuticals, Inc.
$106
Myovant Sciences Inc.
$105
Takeda Pharmaceuticals U.S.A., Inc.
$94
Emmaus Medical, Inc.
$93
Novocure Inc.
$92
Karyopharm Therapeutics Inc.
$89
BeiGene USA, Inc.
$87
Seattle Genetics, Inc.
$77
EISAI INC.
$76
Amneal Pharmaceuticals LLC
$73
Ipsen Biopharmaceuticals, Inc
$73
Cook Medical LLC
$72
Apellis Pharmaceuticals, Inc.
$71
Tempus AI, Inc
$71
AVEO Pharmaceuticals, Inc.
$71
Mirati Therapeutics, Inc.
$70
RECORDATI_RARE_DISEASES_INC.
$66
Acceleron Pharma, Inc.
$65
Acrotech Biopharma LLC
$64
PUMA BIOTECHNOLOGY, INC.
$64
JAZZ PHARMACEUTICALS INC.
$63
US Oncology Corporate, Inc.
$61
MorphoSys, US Inc.
$60
Dendreon Pharmaceuticals LLC
$58
ImmunoGen, Inc.
$56
Taiho Oncology, Inc.
$52
Alexion Pharmaceuticals, Inc.
$52
Pharmacyclics LLC, an AbbVie Company
$52
Jazz Pharmaceuticals Inc.
$52
Clovis Oncology, Inc.
$50
Alnylam Pharmaceuticals Inc.
$49
AbbVie, Inc.
$47
INSYS Therapeutics Inc
$45
Adaptive Biotechnologies Corporation
$44
Rigel Pharmaceuticals, Inc.
$42
Spectrum Pharmaceuticals Inc.
$41
Aurobindo Pharma USA, Inc.
$41
Puma Biotechnology, Inc.
$40
Dova Pharmaceuticals
$39
Helsinn Therapeutics (U.S.), Inc.
$36
G1 Therapeutics, Inc.
$35
Sobi, Inc
$35
Agios Pharmaceuticals, Inc.
$28
Teva Pharmaceuticals USA, Inc.
$26
Octapharma USA, Inc.
$25
SERVIER PHARMACEUTICALS LLC
$25
TOLMAR Pharmaceuticals, Inc.
$24
Deciphera Pharmaceuticals Inc.
$22
Fresenius Kabi USA, LLC
$22
PharmaEssentia USA Corporation
$21
SpringWorks Therapeutics, Inc.
$21
ADC Therapeutics America, Inc.
$20
SUN PHARMACEUTICAL INDUSTRIES INC.
$20
Secura Bio, Inc.
$20
Geron Corporation
$19
Sun Pharmaceutical Industries Inc.
$18
Antares Pharma, Inc.
$17
Advanced Accelerator Applications
$17
TerSera Therapeutics LLC
$17
EUSA Pharma (US) LLC
$14
Aveo Pharmaceuticals, Inc.
$12
Endo Pharmaceuticals Inc.
$12
Prometheus Laboratories Inc.
$11
Top 3 companies account for 28.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ADSTILADRIN · AKYNZEO · ALIMTA · ALUNBRIG · AUGTYRO · AVASTIN · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BOTOX · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · COOK · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Elahere · Empaveli · Endari · Enhertu · Epkinly · Erleada · FARESTON · FOLOTYN · FOTIVDA · FOUNDATIONACT · FOUNDATIONONE · FOUNDATIONONE LIQUID CDX · Fabhalta · Folotyn · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · HEMADY · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · Monoferric · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OCTAPLAS · OGSIVEO · OJJAARA · OPDIVO · ORGOVYX · OTREXUP · OXBRYTA · Onivyde · Optune · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYRUKYND · Pedmark · Pomalyst · Poteligeo · Proleukin · QINLOCK · QUZYTTIR · REBLOZYL · RETEVMO · RYBREVANT · RYTELO · Reblozyl · Revlimid · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · SYNAGIS · SYNDROS · Stimufend · Stivarga · Sylvant · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VYXEOS · Vectibix · Venclexta · Vitrakvi · XALKORI · XGEVA · XIAFLEX · XPOVIO · XT CDX · XTANDI · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · Zevalin · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (60%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
280
Per 100K population
17.7
County median income
$60,698
Nearest hospital
THOMAS JEFFERSON UNIVERSITY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rubin is a mixed practice specialist, with above-average Medicare volume (top 13% in PA), with low-engagement industry engagement in the top 11% of PA peers, with 21 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rubin experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Rubin performed 18,000 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rubin receive payments from pharmaceutical companies?
Yes. Dr. Rubin received a total of $33,324 from 109 companies across 912 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rubin's costs compare to other hematology & oncology specialists in Philadelphia?
Dr. Rubin's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rubin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Philadelphia
Browse hematology & oncology specialists in Philadelphia ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
TESARO, Inc. Payments to Doctors
See all physicians who received payments from TESARO, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology